EUVIMEDEUVIMED entdecken
Crossref

Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)

Anissa Brahami, James A Karlowsky, Melissa McCracken, George R Golding, Kimberly A Nichol, Melanie R Baxter, Heather J Adam iD, Philippe R S Lagacé-Wiens iD, George G Zhanel

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Anissa Brahami und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winn…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Cross Infection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: University of Manitoba, Shared Health, the National Microbiology Laboratory, Avir Pharma Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study reviewed the patient demographic parameters, molecular characteristics and in vitro antimicrobial susceptibility testing results for MRSA isolates infecting inpatients and outpatients presenting for care to tertiary-care Canadian hospitals between 2007 and 2023.

Methods

DNA sequencing was used to generate spa types. Panton-Valentine leukocidin (PVL) genes were detected by PCR. Broth microdilution antimicrobial susceptibility testing (CLSI M7, 12th edition, 2024) was performed with MICs interpreted by CLSI M100 breakpoints (34th edition, 2024) when available.

Results

In total, 2697 MRSA were identified among 12734 Staphylococcus aureus isolates submitted to the CANWARD study between 2007 and 2023. The annual proportion of MRSA decreased significantly from 2007 (26.1%) to 2017 (16.0%) and then increased to 24.2% in 2023 (P < 0.0001). From 2007 to 2023, community-associated (CA)-MRSA spa types increased from 20.8% to 75.0% (P < 0.0001), while hospital-associated (HA)-MRSA decreased from 79.2% to 25.0% (P < 0.0001). The predominant MRSA spa types identified among all isolates were t002 (36.3%), an HA-MRSA genotype, and t008 (24.5%), a CA-MRSA genotype. PVL was detected in 36.0% of all MRSA isolates (76.3% of CA-MRSA; 2.7% of HA-MRSA). Percent susceptible values for all MRSA isolates were ≥99% for ceftobiprole, dalbavancin, daptomycin, linezolid, nitrofurantoin and vancomycin. Notable differences in percent susceptible values were identified for clindamycin (HA-MRSA, 38.9%; CA-MRSA, 86.9%) (P < 0.0001) trimethoprim/sulfamethoxazole (HA-MRSA, 91.4%; CA-MRSA, 98.8%) (P < 0.0001) and doxycycline (HA-MRSA, 96.6%; CA-MRSA, 98.8%) (P = 0.0003).

Conclusions

The changing epidemiology of MRSA in Canadian hospitals warrants continued national surveillance efforts as a resource to support therapeutic guidelines and infection control and prevention programmes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsCross InfectionHumansCanadaMicrobial Sensitivity TestsMiddle AgedMaleFemaleLeukocidinsAgedAnti-Bacterial AgentsAdultExotoxinsYoung AdultAdolescentBacterial ToxinsAged, 80 and overHospitalsTertiary Care CentersChildCommunity-Acquired InfectionsChild, Preschool

Substanzen

LeukocidinsPanton-Valentine leukocidinAnti-Bacterial AgentsExotoxinsBacterial ToxinsVirulence Factors

Autor:innen und Institutionen

  • Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0J9.
  • Clinical Microbiology, Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9.
  • National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3M4.

ORCID-Profile: Heather J Adam, Philippe R S Lagacé-Wiens

Förderung

  • University of Manitoba
  • Shared Health, the National Microbiology Laboratory
  • Avir Pharma Inc.
  • Iterum Therapeutics
  • Merck Canada Inc.
  • Paladin Labs
  • Pfizer
  • Sandoz Canada

Zitieren

APA

Brahami, A., Karlowsky, J. A., McCracken, M., Golding, G. R., Nichol, K. A., Baxter, M. R., Adam, H. J., Lagacé-Wiens, P. R. S., & Zhanel, G. G. (2025). Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf218

Vancouver

Brahami A, Karlowsky JA, McCracken M, Golding GR, Nichol KA, Baxter MR, et al. Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf218

BibTeX
@article{Brahami2025,
  author = {Brahami, Anissa and Karlowsky, James A and McCracken, Melissa and Golding, George R and Nichol, Kimberly A and Baxter, Melanie R and Adam, Heather J and Lagacé-Wiens, Philippe R S and Zhanel, George G},
  title = {Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf218}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche